Related Experiment Video
Updated: Aug 17, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Phase II study in advanced sarcoma: randomized trial of pyrazofurin versus combination cyclophosphamide, doxorubicin,
Abstract:
Twenty-eight patients with various histologic types of measurable metastatic sarcoma were randomly assigned to receive treatment with combination cyclophosphamide, doxorubicin (Adriamycin), and cis-dichlorodiammineplatinum(II) (CAP) or the single-agent, pyrazofurin. Patients who failed one arm of the protocol were eligible for cross-over treatment. Six of 24 patients treated with CAP achieved objective tumor regressions (25%), with a median duration of 11 months. None of 21 patients receiving pyrazofurin achieved a response. CAP is an effective, well-tolerated combination for the treatment of advanced sarcoma.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020